

Advanced Therapies in London and the Greater South East (GSE)

MedCity can help you navigate and access different parts of the academic, NHS and industrial life sciences and healthcare environment across the golden triangle of Cambridge, London, Oxford and the greater south east region of England.

office@medcityhq.com
 +44 (0)20 3179 8100
medcityhq.com
 @MedCityHQ

Advanced therapies are products using gene therapy, cell therapy, and/or tissue engineering, and are used to treat diseases and injuries.

They can be classified into three main categories:



Gene Therapy Medicines

Genes that have a therapeutic, prophylactic or diagnostic effect.



Somatic-Cell Therapy Medicines

Tissues/cells manipulated to change their biological characteristics, or not intended to be used for the same essential functions in the body.



Tissue-Engineered Medicines

Tissues/Cells modified so that they can be used to replace, repair or regenerate human tissue.

A Rich Ecosystem

Home to:

- 80+ advanced therapies companies in GSE, more than 60% of UK advanced therapies companies
- Significant translational research and clinical trials capability
- Strong track record of spinout company formation from universities across the region



Key companies have made their home in the region


- | | | |
|------------------|-------------|----------------------|
| Oxford BioMedica | Immunocore | Autolus |
| Adaptimmune | Cell Medica | Orchard Therapeutics |

For a complete list of companies in the region, please visit medcitymap.com

Investment

Home to:

- Cleanroom footprint (London) **806.5m²**
- £85m+** government funding into the Cell and Gene Therapy Catapult
- £3bn+** funding raised by advanced therapies companies from 2014 -18²
- Funding increase of **35%** from 2017-18²
- £5m Research England funding to set up London Advanced Therapies



World Class Collaborations



100,000 GENOMES PROJECT: 100,000 whole genomes sequences from 85,000 patients, with a focus on rare diseases and cancer

COLLABORATE TO INNOVATE: A £3.5m programme connecting SMEs with leading academics, managed by MedCity and funded by European Regional Development Fund (ERDF) and Research England

NHS AND NOVARTIS: Deal brought CAR-T (immuno-oncology) therapy for childhood leukaemia to NHS England patients

TRANSLATIONAL MEDICINE HUBS: 8 (out of 11) National Institute for Health Research (NIHR) Biomedical Research Centres (BRCs), which act as hubs for translational medicine, include advanced therapies in their research portfolio

ADVANCED THERAPIES NETWORK:

Launched in 2018, to connect research expertise and industry. To find out more and to join the network, please visit advancedtxnetwork.co.uk

LONDON ADVANCED THERAPIES: Catalyses London's capabilities in Advanced therapies by fostering collaborative work, facilitating commercial partnerships and creating a microclimate for innovation. Funded by Research England and delivered by King's College London, Imperial College London, UCL and MedCity

Research Excellence



Home to pioneering hospitals developing and delivering advanced therapies

In 2019 an 11-year-old boy became **the first NHS patient** to receive a pioneering new cancer therapy at the world-renowned Great Ormond Street Hospital (GOSH)

The Cell and Gene Therapy Catapult: Supporting advanced therapies businesses by providing manufacturing, clinical trials, regulatory and market access expertise

14 cell and/or gene therapy manufacturing GMP-standard centres, including the £60m Cell and Gene Therapy Catapult Manufacturing Centre at Stevenage

Over 85 cell and gene therapy trials in the UK in 2018⁵; 43 of the 52 gene therapy trials are taking place in London⁶

Access to Talent



Universities in the region deliver the highest standards of clinical and research training in advanced therapies

Four of the world's top 20, and **three** of the world's top 10 universities³

192,000+ life sciences students in 2017/18, **134,200+** undergraduate and **18,480+** doctoral students⁴

58,100+ life sciences qualifiers in 2017/18, **21,000+** with a postgraduate degree⁴

The Francis Crick Institute: a collaboration between Cancer Research UK, Imperial College London, King's College London, the Medical Research Council, UCL, and the Wellcome Trust. Provides access to talent and leading research on stem cells, genome integrity and repair

¹Cell and Gene Therapy GMP manufacturing in the UK; 2018

²Pitchbook data

³QS Rankings 2019

⁴HESA data 2017/18

⁵Cell and Gene Catapult, 2018

⁶clinicaltrials.gov data, 2018